Topic
Topic
Nature published a piece claiming a psoriasis cure could be "in touching distance" — a headline that reframes a chronic disease as potentially curable, and puts the burden on trials to prove it.
Johnson & Johnson reports robust two-year data for ICOTYDE (icotrokinra) in plaque psoriasis across adults and adolescents, posit…
Bioengineer.org this week reported a dual cytokine blocker held psoriasis in remission for two full years. The molecule hits two…
Johnson & Johnson has reported that at least 72% of patients in a long-term psoriasis cohort hit PASI 90 at two years. Here's wha…
A 25 September 2026 Journal of Dermatological Science paper from Kenney et al. reports baricitinib upregulates filaggrin and lori…
Two-year ICONIC-LEAD data show oral IL-23 receptor antagonist icotrokinra sustained skin clearance in plaque psoriasis, strengthe…
The FDA has approved icotrokinra, the first oral IL-23 receptor antagonist for psoriasis, giving dermatologists a tablet-based op…
A Nature review argues psoriasis immunogenetics — from HLA variants to IL-23/TH17 pathway genetics — is ready to move from discov…
